84results about How to "Inhibit oxidative stress" patented technology

A unique DHA product, 10, 17S-docosatriene (“Neuroprotectin D1” or “NPD1”), was found to provide surprisingly effective neuroprotection when administered right after an experimental stroke. Moreover, both nerve cells and retinal pigment epithelial (RPE) cells were found to synthesize 10,17S-docosatriene (NPD1) from DHA. NPD1 also potently counteracted H2O2 / TNFα oxidative stress-mediated cell apoptotic damage. Under the same oxidative-stress conditions, NPD1 up-regulated the anti-apoptotic Bcl-2 proteins, Bcl-2 and Bcl-xL, and decreased expression of the pro-apoptotic proteins, Bad and Bax. Moreover, in RPE cells NPD1 inhibited oxidative stress-induced caspase-3 activation, IL-1β-stimulated human COX-2 promoter expression, and apoptosis due to N-retinylidene-N-retinylethanolamine (A2E). Overall, NPD1 protected both nerve and retinal pigment epithelial cells from cellular apoptosis and damage due to oxidative stress. NPD1 concentration in the brain of Alzheimer's patients was found to be significantly decreased from that of controls. In cultured human brain cells, NPD1 synthesis was up-regulated by neuroprotective soluble β amyloid, and NPD1 was found to inhibit secretion of toxic β amyloid peptides.

A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier. The combination containing pterostilbene and curcumin is effective for treatment or prevention of oxidative stress, treatment of digestive disorders including inflammatory bowel disease, and / or to reduce or inhibit inflammation, in both animals and in humans.

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

A method of treating and / or preventing oxidative damage, comprising administering an effective IsoK / NeuroK adduct formation suppressing amount of a phenolic amine compound and / or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.

The disclosure provides compositions treating traumatic brain injuries such as concussions. In one embodiment, the composition comprises phosphatidylserine, phosphatidylcholine, quercetin, astaxanthin, R-alpha lipoic acid, N-acetyl cysteine, taurine, L-glutamine, carnitine, D-ribose, creatine, epigallocatechin gallate, melatonin, ginkgo leaf extract, curcumin and L-glycine. The disclosure also provides methods for treating traumatic brain injuries such as concussions by administering an effective amount of the compositions described within.

Veterinary supplements comprising one or more Nrf2-activating agents are disclosed. The veterinary supplements may further comprise omega-3 fatty acids and collagen. The veterinary supplements are effective for treating, inhibiting, reducing and / or preventing oxidative stress.

The invention discloses a hyaluronic acid skin protection composition. The hyaluronic acid skin protection composition comprises: 1) a sulfhydrylated derivative of hyaluronic acid; and 2) at least one molecular weight of hyaluronic acid or salt thereof. The composition has unique advantages when used for skin protection, not only has multiple skin protection effects of the hyaluronic acid, but also has strong antioxidant capacity, and can effectively scavenge active oxygen radicals.

The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the active ingredient is trehalose. Also, it contains at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides having lubricating properties. This solution for tissue adhesion prevention is provided as any form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid.

The invention discloses a multifunctional lactobacillus fermentum CCFM1051 for relieving PFOA toxicity and fermented foods and application thereof. The invention screens out probiotics which have highadsorption capacity on PFOA, do not colonize in human bodies and have high oxidation resistance; and the probiotics not only can inhibit oxidative stress caused by the PFOA, but also can fundamentally eliminate the PFOA in human bodies. The lactobacillus fermentum CCFM1051 can be used for preparing foods, health products and medicines with PFOA toxicity relieving effect, and has wide applicationprospect.

In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.

The invention discloses a drug novel use of fucoidan polysaccharide sulfate. The use is the application of the fucoidan polysaccharide sulfate in preparing the following products: (1), a product for preventing and / or treating diabetic cardiomyopathy; (2), a product for inhibiting diabetic myocardial oxidative stress; and (3), a product for inhibiting expression and activation of PKC (Protein Kinase C) beta in diabetic cardiomyopathy; and (4), a product for relieving cardiac interstitial fibrosis of a diabetic. The fucoidan polysaccharide sulfate is preferably LMWF (Fucoidan Polysaccharide Sulfate) with weight-average molecular weight of 3-30KD. According to the pharmacodynamic experiment, the LMWF can be used for generating beneficial interference to the development of pathogenetic condition of the diabetic cardiomyopathy by strengthening the myocardial systolic function and relieving cardiac fibrosis. More importantly, the LMWF can be used for effectively inhibiting oxidative stress by regulating the activity of antioxidase, and can be used for inhibiting the expression of protein kinase C beta (PKCbeta) subtype. The LMWF is from the natural existing kelp, so that the availability and safety of the kelp are beneficial to using the fucoidan polysaccharide sulfate as a potential clinical treatment drug and preventing the diabetic cardiomyopathy.

The invention belongs to the field of research and development of polypeptide medicines and discloses a scorpion venom heat-resistant synthetic peptide and application thereof. An amino acid sequence of an SVHRP (scorpion venom heat-resistant peptide) is detected out from BmK (Buthus martensii Karsch) which is a traditional Chinese medicine; according to animal experiment verification, a scorpion venom heat-resistant peptide extract liquid sample has pharmacological activity in prevention and treatment of intractable epilepsy, Parkinson's disease and Alzheimer's disease, the sample is subjected to LaGm composite and repeated fast magnetic separation prior to nanoLC-ESI-MS (nano-liter reversed-phase chromatography and electrospray ionization mass spectrometry) integrated mass spectrometry parallel experiment to detect out a polypeptide sequence formed by 15 amino acid residues. The scorpion venom heat-resistant synthetic peptide is prepared by solid-phase chemical synthesis, chromatography purification and mass spectrometry identification. An amino acid sequence of the scorpion venom heat-resistant synthetic peptide is as shown in SEQ ID NO.1 and keeps pharmacological activity and safety of the scorpion venom heat-resistant peptide, and the scorpion venom heat-resistant peptide also has a characteristic of biological activity in promotion of reverse differentiation of neuroglial cells into neural stem cells.

The invention relates to the technical field of biological medicines. That miR-144 can specifically inhibit the gene expression of Nrf2 is disclosed for the first time, the expression of miR-144 is closely related to heart disease, and the high expression of miR-144 can promote myocardial oxidative stress to cause myocardial damage related diseases. The invention provides miR-144 and application of an inhibitor of miR-144 in preparation of medicines for preventing or treating myocardial oxidative stress and damage diseases, especially diabetes caused myocardial oxidative stress and damage diseases; a new target spot is provided for the diagnosis and prevention and treatment of heart diseases.

The invention relates to a biological medicine domain, particularly a pharmaceutical application of a protein associated with activation of human hepatic stellate cell, namely an application of preparation of medicine for liver diseases. The invention also discloses a recombination preparation method.

The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor γ nuclear translocation, and inhibit nuclear transcription factor NF-κB nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.

The invention provides application of Vietnamese ginsenoside R4 in preparation of a medicament for treating neurodegenerative diseases, in particular to the application in preparation of a medicamentfor treating Parkinson's disease. According to the application, by designing an in-vitro Parkinson model, Vietnamese ginsenoside R4 is proposed for the first time and proves to be capable of reducingcell damage, and the resistance effect on Parkinson disease is achieved by inhibiting oxidative stress of cells and regulating cell apoptosis. Therefore, the application of Vietnamese ginsenoside R4 as an effective medicament for treating Parkinson disease provides a basis for developing and expanding the medicament application of Vietnamese ginsenoside R4.

The invention discloses application of fructus chaenomelis betulinic acid in preparing a medicine for resisting hypertensive myocardial fibrosis, and belongs to the technical field of biological medicines. The fructus chaenomelis betulinic acid is applied to treat treating spontaneously hypertensive rats (SHR), and the result shows that after drug administration treatment for 12 weeks, blood pressure of each group of SHR is reduced, and serum endothelin (ET) contents of each dosage group of fructus chaenomelis betulinic acid and a captopril CAP group are remarkably reduced; the nitric oxide (NO) content is remarkably improved; according to each dosage group of fructus chaenomelis betulinic acid, the contents of MCP-1, TNF-alpha, IL-1, IL-6, CRP and MDA can be reduced, so that the result shows that the fructus chaenomelis betulinic acid can be beneficial to reducing of the content of cardiac muscle tissue inflammatory factors, reducing of damage of oxidative stress on tissues, improvingof tissue oxidation resistance, and improving of myocardial fibrosis through multiple target points.

The invention relates to a compound fructus crataegi-turmeric root tuber particle, which is prepared from the following bulk pharmaceuticals in parts by weight: 130-170 parts of fructus crataegi, 60-90 parts of turmeric root tuber, 60-90 parts of oriental waterplantain rhizome, 80-120 parts of seaweed, 60-90 parts of bulb of thunberg fritillary, 80-120 parts of milk thistle and 40-60 parts of peach kernel. The invention further provides a preparation method for the compound fructus crataegi-turmeric root tuber particle. The method comprises the following steps of: weighing fructus crataegi, turmeric root tuber, oriental waterplantain rhizome, seaweed, bulb of thunberg fritillary, milk thistle and peach kernel according to parts by weight, and adding water for soaking; preparing micro-powder silica gel serving as a single auxiliary material of spray drying and lactose serving as an auxiliary material of particle forming, and standing for later use; adding water in an amount which is 4-10 times that of soaked Chinese medicinal materials including fructus crataegi, turmeric root tuber, oriental waterplantain rhizome, seaweed, bulb of thunberg fritillary, milk thistle and peach kernel for a first time, adding water in an amount which is 4-10 times that of the Chinese medicinal materials for a second time, and decocting; concentrating an obtained compound extract till the relative density is 1.065, adding an auxiliary material, i.e., micro-powder silica gel, performing spraying drying to obtain extract powder; and adding lactose and ethanol into the extract powder, uniformly mixing, granulating, drying and regulating particles.

The invention discloses an extract of Glycine tabacina (Labill.) Benth. The extract contains isoflavones, triterpenoids, scoparone and vanillic acid. The results of pharmacodynamic experiments show that the extract of Glycine tabacina (Labill.) Benth has obvious therapeutic effect on arthritis, can significantly reduce the degenerative changes of bones and destroy to cartilago articularis, decreases the expression of pro-inflammatory cytokines, inhibits oxidative stress, and provides a novel medication option for clinical treatment of arthritis.

The invention provides an application of dendrobium polysaccharide in the preparation of drugs for prevention and treatment of reproductive injury caused by arsenic poisoning. The dendrobium polysaccharide has obvious therapeutic effect on reproductive injury induced by arsenic exposure in male rats, which can significantly increase the number and motility of sperms, increase the incidence of sperm acrosome reaction and decrease the rate of sperm deformity; the SOD activity, GPx activity, CAT activity and GSH content in testicular tissue are also significantly increased, while MDA content is also significantly decreased; the dendrobium polysaccharide has rarely toxic and side effects and no adverse effect on normal growth and physiological state. The dendrobium polysaccharide with wide source of raw materials is simple in extraction and purification method, high in sugar content and suitable for large-scale production and promotion and has a good prospect in the preparation and / or treatment of reproductive injury drugs caused by arsenic poisoning and clinical application.

An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts / compositions, as well as corresponding methods of treatment, for example as an antioxidant or to decrease or inhibit oxidative stress in a cell, tissue or subject are also described.

The invention discloses an application of oltipraz in preparation of a product for preventing and treating osteoporosis. The application comprises any one of the following items: 1) preparing a product for preventing and treating osteoporosis caused by lack of active vitamin D; 2) preparing a product for preventing and treating osteoporosis caused by estrogen deficiency; and 3) preparing a product for preventing and treating osteoporosis caused by vitamin D receptor deficiency. According to the invention, through a test of supplementing an Nrf2 agonistoltiprazto a mouse model, the effect and related mechanism of oltipraz in preventing and treating osteoporosis caused by lack of active vitamin D are disclosed, and meanwhile, experimental and theoretical bases are provided for the application of oltipraz in preventing and treating osteoporosis caused by estrogen deficiency.

The invention provides an oxidative stress intervening and anticoagulation hemodialysis membrane and a preparation method and application thereof, and belongs to the technical field of membranes. Themethod comprises the following steps: 1) preparing a plant polyphenol mixed solution; 2) preparing a polyoxazoline mixed solution; 3) preparing an anticoagulant mixed solution; 4) enabling the plant polyphenol mixed solution to flow through a hemodialysis membrane at a constant temperature; 5) enabling the polyoxazoline mixed solution to flow through the plant polyphenol modified hemodialysis membrane at the constant temperature; and 6) enabling the anticoagulant mixed solution to flow through a hemodialysis membrane of the plant polyphenol-polyoxazoline modified hemodialysis membrane to obtain a product at the constant temperature. The membrane is mainly used for hemodialysis and can effectively achieve the purposes of inhibiting oxidative stress and preventing thrombus on the premise ofgood biocompatibility.

The invention relates to application of mulberry particles to preparation of medicines for preventing and treating diabetes and complications thereof. The complications refer to one of cardiovascular diseases, cerebrovascular diseases, renal injuries and vascular injuries. The mulberry particles are especially excellent in prevention and treatment effect on cardiovascular disease complications of diabetes and particularly prominent in treatment effect on cardiac dysfunction, myocardial injuries or myocardial infarction caused by myocardial ischemia. Furthermore, the mulberry particles are effective in control of in-vivo blood sugar and blood lipid level of patients suffering from diabetes, capable of improving cardiac dysfunction caused by myocardial ischemia with diabetes and effective in inhibition of oxidative stress.